Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Purvi Saraiya

Neurology Toledo, OH Medical Doctor

NPI 1588612725 CMS profile 207838

4235 Secor Rd, Toledo, OH 43623

Open in the dashboard

General payments

$28,686

1,575 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Purvi Saraiya of Toledo, OH is reported in the CMS Open Payments database as having received $28,686 across 1,575 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,143 220
2024 General $4,112 222
2023 General $5,594 235
2022 General $4,553 268
2021 General $4,130 238
2020 General $2,716 172
2019 General $3,439 220

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Purvi Saraiya
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Purvi Saraiya were reported at $4,143. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Purvi Saraiya Neurology median Middle half National median
2019 $3,439 $474 $118–$2,177 $163
2020 $2,716 $367 $82–$2,309 $114
2021 $4,130 $438 $104–$2,547 $132
2022 $4,553 $442 $103–$2,388 $149
2023 $5,594 $464 $119–$2,312 $160
2024 $4,112 $468 $119–$2,323 $164
2025 $4,143 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. EMD Serono, Inc. $3,132 131 payments
  2. Biogen, Inc. $2,102 128 payments
  3. Novartis Pharmaceuticals Corporation $2,099 120 payments
  4. AbbVie, Inc. $2,084 133 payments
  5. Teva Pharmaceuticals USA, Inc. $1,505 97 payments
  6. LivaNova USA, Inc. $1,473 11 payments
  7. UCB, Inc. $1,291 90 payments
  8. SK Life Science, Inc. $1,241 85 payments
  9. ACADIA Pharmaceuticals Inc $963 78 payments
  10. Alexion Pharmaceuticals, Inc. $954 41 payments
  11. Other $11,841 661 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $26,791 1,546 payments
  2. Travel and Lodging $1,008 3 payments
  3. Education $725 15 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $162 11 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $1,548 101 payments
  2. VNS Therapy $1,384 5 payments
  3. UBRELVY $1,167 80 payments
  4. Briviact $1,020 71 payments
  5. QULIPTA $1,004 57 payments
  6. VUMERITY $943 61 payments
  7. OCREVUS $850 44 payments
  8. KESIMPTA Neuroscience $809 43 payments
  9. KESIMPTA Neurology $733 45 payments
  10. AIMOVIG $598 32 payments
  11. Other $18,894 1,123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

4,655

Median for Neurology: 833

Drug cost

$1,668,106

Median for Neurology: $202,670

Branded share of claims

30.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rebif Interferon Beta-1a/Albumin Brand 22 $250,375
Austedo Xr Deutetrabenazine Brand 28 $203,797
Kesimpta Pen Ofatumumab Brand 18 $155,559
Vumerity Diroximel Fumarate Brand 15 $150,166
Avonex Pen (4 Pack) Interferon Beta-1a Brand 13 $108,335
Aptiom Eslicarbazepine Acetate Brand 32 $89,170
Copaxone Glatiramer Acetate Brand 14 $75,793
Xcopri Cenobamate Brand 48 $74,674
Emgality Pen Galcanezumab-Gnlm Brand 75 $54,792
Nurtec Odt Rimegepant Sulfate Brand 47 $53,349

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$81,178

Medicare's payments for the services billed

Medicare patients

591

Average age 74

Services billed

1,054

354 women, 237 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Depression 34%
Diabetes 33%
Chronic kidney disease 29%
Ischemic heart disease 27%
COPD 20%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 43 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
$380 18 —
NOURIANZ
$207 — —
ULTOMIRIS
$196 — —
FYCOMPA
$177 — —
ZEPOSIA
$172 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 43 with Patron

Records

1,575 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record